Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ACN
6. AZN
7. ROIV
8. AAPL
9. QCOM
10. NVDA

Go back to Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) Delayed: 27.99 -0.03 (0.11%)
Previous Close $28.02    52 Week High $42.49 
Open $27.63    52 Week Low $16.64 
Day High $28.09    P/E N/A 
Day Low $27.10    EPS $-0.42 
Volume 854,646